TrialHaematologica2023

Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.

Grégoire Stalder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.